Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-019-0525-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum free light chain level-based and non-fixed cycle daratumumab treatment strategy for patients with light chain amyloidosis.
Ann Med
December 2025
National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: In recent years, daratumumab (DARA) has gained widespread use in the treatment of systemic light chain (AL) amyloidosis. In this study, we assessed the efficacy and safety of a DARA treatment strategy based on serum free light chain (sFLC) levels and non-fixed cycles.
Methods: The study included 123 patients with Al amyloidosis who received DARA at our center between July 2020 and September 2023.
The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA.
Bone Marrow Transplant
November 2024
Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Pure red cell aplasia (PRCA) and autoimmune hemolytic anemia (AIHA) post-hematopoietic stem cell transplantation (HSCT) are an unmet medical need with no established standard of care, significantly affecting the patient quality of life and posing a challenge for clinicians. The anti-CD38 IgG-kappa Daratumumab appears to be a safe and efficace treatment compared to prior drugs. Our study is a prospective monocentric investigation assessing the use of daratumumab in these complications following allo-HSCT.
View Article and Find Full Text PDFA Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India.
Indian J Hematol Blood Transfus
October 2024
Department of Transfusion Medicine, Tata Medical Center, Newtown, Rajarhat, 700160 Kolkata, India.
Unlabelled: The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration.
View Article and Find Full Text PDFA plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma.
Future Oncol
October 2024
Dana-Farber/Partners CancerCare, Harvard Medical School, Boston, MA, USA.
What Is This Summary About?: This summary describes the final analysis of the GRIFFIN study. In this study, participants were newly diagnosed with a type of blood and bone marrow cancer called multiple myeloma, had never received any treatment, and were able to undergo an autologous stem cell transplant. The GRIFFIN study looked at adding the drug daratumumab (D) to a combination of standard treatments called RVd (lenalidomide [R], bortezomib [V], and dexamethasone [d]) during the treatment phases induction and consolidation, followed by daratumumab and lenalidomide (D-R) maintenance.
View Article and Find Full Text PDFIsolated central nervous system (CNS) relapse of multiple myeloma 11 years after autologous stem cell transplantation: a case report.
AME Case Rep
September 2024
Hemato-oncologic specialties center (CEDEHO), Spanish Hospital of Mexico, Mexico City, Mexico.
Background: Multiple myeloma (MM) relapse in the central nervous system (CNS) confers an adverse prognosis, usually occurring in a short period after stem cell transplant and with a short overall survival. Isolated CNS relapse is so rare that there is no current standard treatment.
Case Description: We present a 59-year-old male with an isolated CNS MM relapse, who had received autologous stem-cell transplant (ASCT) and thalidomide maintenance 11 years prior.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!